Toti Kiran S, Moss Steven M, Paoletta Silvia, Gao Zhan-Guo, Jacobson Kenneth A, Van Calenbergh Serge
Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Gent, Belgium.
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Bioorg Med Chem. 2014 Aug 1;22(15):4257-68. doi: 10.1016/j.bmc.2014.05.036. Epub 2014 May 23.
Adenosine receptors (ARs) trigger signal transduction pathways inside the cell when activated by extracellular adenosine. Selective modulation of the A₃AR subtype may be beneficial in controlling diseases such as colorectal cancer and rheumatoid arthritis. Here, we report the synthesis and evaluation of β-D-apio-D-furano- and α-D-apio-L-furanoadenosines and derivatives thereof. Introduction of a 2-methoxy-5-chlorobenzyl group at N(6) of β-D-apio-D-furanoadenosine afforded an A₃AR antagonist (10c, Ki=0.98 μM), while a similar modification of an α-D-apio-L-furanoadenosine gave rise to a partial agonist (11c, Ki=3.07 μM). The structural basis for this difference was examined by docking to an A₃AR model; the antagonist lacked a crucial interaction with Thr94.
腺苷受体(ARs)在被细胞外腺苷激活时会触发细胞内的信号转导途径。对A₃AR亚型的选择性调节可能有助于控制诸如结直肠癌和类风湿性关节炎等疾病。在此,我们报告了β-D-阿皮奥-D-呋喃核糖基腺苷和α-D-阿皮奥-L-呋喃核糖基腺苷及其衍生物的合成与评估。在β-D-阿皮奥-D-呋喃核糖基腺苷的N(6)位引入2-甲氧基-5-氯苄基得到一种A₃AR拮抗剂(10c,Ki = 0.98 μM),而对α-D-阿皮奥-L-呋喃核糖基腺苷进行类似修饰则产生一种部分激动剂(11c,Ki = 3.07 μM)。通过与A₃AR模型对接研究了这种差异的结构基础;该拮抗剂与Thr94缺乏关键相互作用。